Tau and α-synuclein pathology in amygdala of parkinsonism-dementia complex patients of Guam

被引:108
作者
Forman, MS
Schmidt, ML
Kasturi, S
Perl, DP
Lee, VMY
Trojanowski, JQ
机构
[1] Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA
[2] Mt Sinai Sch Med, Dept Pathol, New York, NY USA
[3] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA
关键词
D O I
10.1016/S0002-9440(10)61119-4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC) is a progressive neurodegenerative disorder of Chamorro residents of Guam and the Mariana islands, characterized by abundant neuron loss and tau neurofibrillary pathology similar to that observed in Alzheimer's disease (AD). A variety of neurodegenerative diseases with tau pathology including ALS/PDC also have alpha-synuclein positive pathology, primarily in the amygdala. We further characterized the tau and alpha-synuclein pathology in the amygdala of a large series of 30 Chamorros using immunohistochemical and biochemical techniques. Tau pathology was readily detected in both affected and unaffected Chamorros. In contrast, alpha-synuclein pathology was detected in 37% of patients with PDC but not detected in Chamorros without PDC or AD. The alpha-synuclein aggregates often co-localized within neurons harboring neurofibrillary tangles suggesting a possible interaction between the two proteins. Tau and alpha-synuclein pathology within the amygdala is biochemically similar to that observed in AD and synucleinopathies, respectively. Thus, the amygdala may be selectively vulnerable to developing both tau and alpha-synuclein pathology or tau pathology may predispose it to synuclein aggregation. Furthermore, in PDC, tau and alpha-synuclein pathology occurs independent of beta-amyloid deposition in amygdala thereby implicating the aggregation of these molecules in the severe neurodegeneration frequently observed in this location.
引用
收藏
页码:1725 / 1731
页数:7
相关论文
共 55 条
[1]   Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies [J].
Arima, K ;
Hirai, S ;
Sunohara, N ;
Aoto, K ;
Izumiyama, Y ;
Uéda, K ;
Ikeda, K ;
Kawai, M .
BRAIN RESEARCH, 1999, 843 (1-2) :53-61
[2]  
Baba M, 1998, AM J PATHOL, V152, P879
[3]   Tau protein isoforms, phosphorylation and role in neurodegenerative disorders [J].
Buée, L ;
Bussière, T ;
Buée-Scherrer, V ;
Delacourte, A ;
Hof, PR .
BRAIN RESEARCH REVIEWS, 2000, 33 (01) :95-130
[4]  
BUEESCHERRER V, 1995, AM J PATHOL, V146, P924
[5]   NEUROFIBRILLARY CHANGE ON GUAM [J].
CHEN, L .
ARCHIVES OF NEUROLOGY, 1981, 38 (01) :16-18
[6]  
DAMATO CJ, 1991, J NEUROPATH EXP NEUR, V50, P308
[7]  
Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO
[8]  
2-4
[9]   New insights into genetic and molecular mechanisms of brain degeneration in tauopathies [J].
Forman, MS ;
Lee, VMY ;
Trojanowski, JQ .
JOURNAL OF CHEMICAL NEUROANATOMY, 2000, 20 (3-4) :225-244
[10]   PROGRESSIVE SUPRANUCLEAR PALSY - NEUROPATHOLOGIC AND CLINICAL HETEROGENEITY [J].
GEARING, M ;
OLSON, DA ;
WATTS, RL ;
MIRRA, SS .
NEUROLOGY, 1994, 44 (06) :1015-1024